| 201 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Canada
|
69 |
| 202 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
Italy
|
66 |
| 203 |
Apheresis |
Allogeneic
|
Fanconi Anemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
4 |
| 204 |
Apheresis |
Allogeneic
|
Leukemia T-PLL
|
Hematology
|
2026
|
Standard Therapy
|
Norway
|
64 |
| 205 |
Apheresis |
Allogeneic
|
T-cell NHL Non-Hodgkin Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
46 |
| 206 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
60 |
| 207 |
Apheresis |
Allogeneic
|
MM, Myeloma Multiplex
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
48 |
| 208 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Norway
|
29 |
| 209 |
Apheresis |
Allogeneic
|
Myelofibrosis Myeloid Metaplasia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
27 |
| 210 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Austria
|
34 |
| 211 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes(MDS)
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
55 |
| 212 |
Apheresis |
Allogeneic
|
Thalassemia Major
|
Hematology
|
2026
|
Standard Therapy
|
Turkey
|
11 |
| 213 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Norway
|
59 |
| 214 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
75 |
| 215 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Hungary
|
62 |
| 216 |
Apheresis |
Allogeneic
|
2nd Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
Netherlands
|
67 |
| 217 |
Apheresis |
Allogeneic
|
Acute Myelomonocytic Leukemia (AMML)
|
Hematology
|
2026
|
Standard Therapy
|
Ukraine
|
44 |
| 218 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Portugal
|
59 |
| 219 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
54 |
| 220 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
France
|
67 |
| 221 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Spain
|
47 |
| 222 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Hungary
|
42 |
| 223 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Hungary
|
67 |
| 224 |
Apheresis |
Allogeneic
|
Prolymphocytic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
66 |
| 225 |
Apheresis |
Allogeneic
|
Other Myelofibrosis/Myelosclerosis
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
59 |
| 226 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
52 |
| 227 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Australia
|
57 |
| 228 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Australia
|
56 |
| 229 |
Apheresis |
Allogeneic
|
Chronic Myelomonocytic Leukemia (CMML)
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
56 |
| 230 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Ukraine
|
37 |
| 231 |
Apheresis |
Allogeneic
|
Sickle Cell Anemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
10 |
| 232 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
71 |
| 233 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Canada
|
69 |
| 234 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
France
|
51 |
| 235 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
63 |
| 236 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
65 |
| 237 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Sweden
|
68 |
| 238 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Czechia
|
67 |
| 239 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Spain
|
63 |
| 240 |
Apheresis |
Allogeneic
|
Chronic Lymphocytic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Australia
|
57 |
| 241 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
51 |
| 242 |
Apheresis |
Allogeneic
|
B-Cell Acute Lymphoblastic Leukemia (B-ALL)
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
46 |
| 243 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
59 |
| 244 |
Apheresis |
Allogeneic
|
Primary Myelofibrosis (PMF)
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
59 |
| 245 |
Apheresis |
Autologous
|
T-cell Lymphoblastic Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
40 |
| 246 |
Apheresis |
Autologous
|
Anaplastic Large-Cell Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
68 |
| 247 |
Apheresis |
Autologous
|
Central Nervous System Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
51 |
| 248 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
64 |
| 249 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
58 |
| 250 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
63 |
| 251 |
Apheresis |
Autologous
|
T-Cell Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
68 |
| 252 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
68 |
| 253 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
65 |
| 254 |
Apheresis |
Allogeneic
|
Chronic Myeloid Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
United Kingdom
|
55 |
| 255 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
65 |
| 256 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
Austria
|
43 |
| 257 |
Apheresis |
Allogeneic
|
Chronic Myelomonocytic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
60 |
| 258 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
58 |
| 259 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Spain
|
66 |
| 260 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome IB2
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
59 |
| 261 |
Apheresis |
Allogeneic
|
Myelofibrosis Myeloid Metaplasia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
63 |
| 262 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
Israel
|
74 |
| 263 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
67 |
| 264 |
Apheresis |
Allogeneic
|
Serum Amyloid A (SAA)
|
Hematology
|
2026
|
Standard Therapy
|
United Kingdom
|
11 |
| 265 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
54 |
| 266 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
India
|
52 |
| 267 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
India
|
45 |
| 268 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Spain
|
62 |
| 269 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Netherlands
|
47 |
| 270 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
58 |
| 271 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Lithuania
|
63 |
| 272 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
United Kingdom
|
56 |
| 273 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
72 |
| 274 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
United Kingdom
|
30 |
| 275 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
69 |
| 276 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
70 |
| 277 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Ireland
|
73 |
| 278 |
Apheresis |
Allogeneic
|
Other Leukemia, Specify, Chronic Neutrophilic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
56 |
| 279 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
60 |
| 280 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
Spain
|
64 |
| 281 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
66 |
| 282 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
33 |
| 283 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
Switzerland
|
69 |
| 284 |
Apheresis |
Allogeneic
|
CML Blast Crisis
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
38 |
| 285 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
India
|
34 |
| 286 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
Bulgaria
|
49 |
| 287 |
Apheresis |
Allogeneic
|
Hodgkin lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Russian Federation
|
37 |
| 288 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
65 |
| 289 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
24 |
| 290 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
58 |
| 291 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
69 |
| 292 |
Apheresis |
Allogeneic
|
Chronic Lymphocytic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
63 |
| 293 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Belgium
|
64 |
| 294 |
Apheresis |
Allogeneic
|
Myelofibrosis
|
Hematology
|
2026
|
Standard Therapy
|
Argentine
|
52 |
| 295 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Spain
|
71 |
| 296 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Australia
|
55 |
| 297 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
75 |
| 298 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
69 |
| 299 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
12 |
| 300 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
71 |